Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Verdezyne’s Xylose Isomerase Technology Acquired by DuPont Industrial Biosciences



  Verdezyne’s Xylose Isomerase Technology Acquired by DuPont Industrial
  Biosciences

    Patented Technology Enables Conversion of Biomass Sugars to Fuels and
                                  Chemicals

Business Wire

CARLSBAD, Calif. -- December 17, 2012

Verdezyne, Inc., a privately-held industrial biotechnology company focused on
producing renewable chemicals, announced the sale of its proprietary xylose
isomerase technology, enabling the metabolism of 5-carbon sugars, to DuPont
Industrial Biosciences, a world leader in science and innovation.

Under the terms of the sale, DuPont has purchased rights to Verdezyne’s
patented xylose isomerase technology, covered by U.S. Patent Nos. 8,114,974
and 8,093,037, for use in the rapidly-commercializing biofuels and biochemical
fields. This technology allows the fast and complete utilization of
biomass-sourced C5 sugars in production of various products of choice. This
technological breakthrough was highlighted in a recent Journal of Industrial
Microbiology & Biotechnology article published August 2012.

“Verdezyne’s xylose isomerase technology has been shown to have superior
performance compared to alternatives for converting 5-carbon sugar to fuels
and chemicals,” said E. William Radany, Ph.D., president and CEO of Verdezyne.
“We are pleased that a company of DuPont’s stature recognizes the value of our
proprietary technology.”

“Biomass bioprocessing is opening up unique market opportunities across a wide
range of DuPont businesses and the Verdezyne technology is a natural fit for
the company’s cellulosic portfolio,” said John P. Ranieri, vice president,
DuPont Industrial Biosciences. “The addition of this leading xylose isomerase
technology further strengthens DuPont’s leadership in biomass derived sugar
conversion to biofuels and biochemicals.”

About Verdezyne

Verdezyne is an industrial biotechnology company using proven and proprietary
metabolic pathway engineering tools to develop unique yeast strains for
cost-effective production of bio-based chemicals. Current investors in
Verdezyne include BP Alternative Energy Ventures, DSM Venturing B.V., OVP
Venture Partners and Monitor Ventures. For more information, visit
www.verdezyne.com.

About DuPont Industrial Biosciences

DuPont Industrial Biosciences works with customers across a wide range of
industries to improve products and make processes more sustainable. Through a
unique combination of capabilities in agriculture, biotechnology, chemistry
and material science, coupled with the power of 2,000 talented individuals
worldwide, this DuPont business focuses on providing biobased solutions to
meet the needs of a growing population while protecting our environment.

www.biosciences.dupont.com

Contact:

Verdezyne, Inc.
Aida Yodites, 760-707-5200
Corporate Communications
ayodites@verdezyne.com
or
Sparkpr
Bill Douglass, 646-504-0890
bdouglass@sparkpr.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement